Final overall survival (OS) results from the phase III SOLO2/ENGOT-ov21 trial demonstrated that maintenance olaparib (Lynparza) provided an unprecedented improvement in median OS versus placebo in patients with platinum-sensitive, relapsed ovarian cancer with a BRCA mutation.
Presented at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program, this is the first study with olaparib tablets, and the first since Study 19, to provide long-term follow-up and final OS data in this patient population.
In an interview with CancerNetwork®, Andres Poveda, MD, of the Fundación Instituto Valenciano de Oncologia in Valencia, Spain, discussed the study design and the results presented at the meeting.
Transcription:
The study design is for patients with high-grade serous ovarian cancer and BRCA mutation. Patients were randomized to olaparib tablets or placebo and…
